Page 33 of 87
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version
10-04 :: April 2010

nanotimes

Companies

Facts

certified (UL 1703). The UL Master Certificate is an important validation of product quality and bankabi- lity and will be a key factor for sales of products by Oerlikon Solar customers in the fast-growing market in North America.

Oerlikon Solar has announced an additional TÜV certification for an improved module design, which will provide a stabilized efficiency of 130 Watt-peak (Wp) by the end of 2010.

http://www.oerlikon.com/solar

P

lanar Energy announced, that researchers at the University of Central Florida’s (UCF) Advanced

Materials Processing and Analysis Center (AMPAC)) have verified findings by Planar Energy that could lead to dramatic cost and performance improve- ments in large format batteries required for practical electric vehicles. “AMPAC scientists independently confirmed that Planar Energy’s new generation of

solid state electrolytes have ionic conductivity metrics comparable to liquid electrolytes used in

traditional chemical batteries,” said Dr. M.J. Soile- au, a UCF professor of optics, electrical & computer engineering and physics, who is the university’s vice president for research & commercialization. “This fundamental materials breakthrough, coupled with our proprietary low-cost manufacturing process, will render traditional chemical batteries obsolete,” de- clared Scott Faris, president and CEO of Planar Ener- gy. It will allow solid state battery fabrication that will enable manufacturers to increase their capacity by 200 to 300%, while reducing costs more than 50%.

http://www.planarenergy.com

p

Sivida Corp. (NASDAQ:PSDV) (ASX:PVA) said that a recently-published peer reviewed scien-

tific paper showed that a sustained release Durasert drug delivery device releasing the steroid fluocino- lone acetonide (FA) in the back of the eye preserved retinal function in a retinitis pigmentosa model.

“This is very encouraging,” said Dr. Ashton, CEO of pSivida Corp, “and we intend to pursue further studies using our technologies for the treatment of eye diseases for which there currently are very few effective treatments.” pSivida has developed two of the only three FDA approved ophthalmic sustained release drug delivery products, Retisert® ment of posterior uveitis and Vitrasert®

33

for the treat- for the treat-

ment of Aids-related CMV retinitis, both of which are licensed to Bausch & Lomb. The company’s third product, Iluvien®

for the treatment of diabetic macu-

lar edema is licensed to Alimera Sciences which is conducting Phase III fully recruited trials and expects to submit a New Drug Application to the FDA in the second quarter of this year. If approved, Iluvien will be the first FDA approved drug for the treatment of DME.

http://www.iovs.org/cgi/content/abstract/iovs.09-4492v1

?maxtoshow=&hits=10&RESULTFORMAT=&author1=A shton&fulltext=Retinitis+pigmentosa&andorexactfulltext =and&searchid=1&FIRSTINDEX=0&sortspec=relevance &resourcetype=HWCIT

http://www.psivida.com

Qinetiq (QQ.L); Ruane Cunniff & Goldfarb, a New York fund, bought a 10% stake.

http://www.qinetiq.com

A

rtisan Partners (U.S.), had bought just over 5% of the shares of British defense technology firm
Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87